Concure Oncology revealed on Friday the addition of Scott Armstrong to its board of directors.
As a member of the company's board, Armstrong supports the advancement of Breast Microseed Treatment as well as continue his advocacy for patient-centric care.
Most recently, Armstrong has served as president and CEO of Group Health Cooperative, anot-for-profit health plan company, positions he has held for 12 years.
Previously at Group Health, Armstrong has worked as VP of Network Services, executive VP/chief administrative officer as well as executive VP/chief operating officer.
Scancell initiates SCOPE trial's iSCIB1+ cohort
Bio-Thera Solutions' BAT8006 phase II Study receives US FDA IND approval
Poseida Therapeutics names new chief medical officer
Biocytogen and ABL Bio collaborate on development of new bispecific antibody-drug conjugates
BioVaxys Technology announces non-brokered private placement
Senhwa Biosciences doses first subject in phase II study of Silmitasertib
Antennova completes first dosing cohort in Phase one study of ATN-031
M8 Pharmaceuticals collaborates with SERB Pharmaceuticals
BerGenBio ASA starts Phase 2a portion of BGBC016 clinical study of bemcentinib
Phanes Therapeutics receives FDA Fast Track designation for PT886